TMS Explained: What It Is, How It Works, and Why the Details Matter

TMS uses magnetic pulses to influence brain circuits. The coil, target, dose, and schedule determine what treatment a person is actually receiving.

Direct answer: Transcranial magnetic stimulation, or TMS, is a prescription treatment. It sends brief magnetic pulses through a coil placed on the scalp. The pulses create a small electrical field in nearby brain tissue. TMS can treat certain conditions with specific devices and protocols. It is not one uniform treatment.

Key points

• TMS works through magnetic induction. It does not send electricity through the scalp like an electrode.
• The strongest direct effect is in accessible cortex near the coil. Changes in deeper regions are more likely indirect network effects.
• A device name alone does not identify the coil, target, dose, or schedule.
• FDA status belongs to an exact device and indication. It does not automatically extend to every TMS system.
• Most people stay awake. Scalp discomfort and headache can occur. Seizure is rare but important.

Zoom

What does TMS mean?

“Transcranial” means across the skull. “Magnetic stimulation” describes the physical method. A console sends a fast-changing electrical current through a coil. That current creates a fast-changing magnetic field. The field passes through skin and skull with little resistance. It then creates, or induces, a small electrical field in nearby brain tissue.[1]

That induced field can change when neurons fire. The strongest direct effect is usually in the outer brain tissue. This tissue is called the cortex. Treatment may then affect connected circuits. Think of a train station connected to a larger rail network. Changing activity at one station can affect traffic elsewhere. The analogy has a limit. A brain network is living tissue, not a fixed set of tracks.

TMS does not usually require anesthesia. A person is awake and can speak during a session. This differs from electroconvulsive therapy, or ECT. ECT uses anesthesia and a controlled seizure. Transcranial direct-current stimulation is also different. It uses weak current between scalp electrodes. Magnetic seizure therapy causes a seizure under anesthesia on purpose. Deep brain stimulation requires surgically implanted electrodes.

What happens at a visit?

Before treatment, the team reviews the diagnosis and current symptoms. It also checks medicines, medical history, and sleep. The review covers substance use, seizure risks, and implants. The exact screening follows the device label and clinic procedure. Conductive or magnetic metal near the head may be unsafe. Cochlear implants, implanted stimulators, aneurysm clips, and other devices need a case-specific review. A pacemaker or other implant is not automatically safe or forbidden. The team must check its type, location, label, and specialist guidance.

The clinician may find the motor threshold. This is the lowest machine output under defined conditions. At that output, a small hand muscle responds. The threshold helps set a dose for that person. Motor threshold is a calibration tool. It is not a full measure of how much energy reaches every target. Percent motor threshold is not the same physical dose across unlike coils and stimulators.

The team can find the target in several ways. It may use a scalp rule or head measurements such as Beam F3. It may also use structural MRI, MRI neuronavigation, or functional-connectivity imaging. These methods are not interchangeable. More complex targeting may improve placement accuracy. Yet more technical detail does not prove better outcomes unless a clinical comparison supports it.

During treatment, the coil rests against the scalp. The patient hears clicks. They may feel tapping, tingling, or pressure. Nearby face or scalp muscles may move. Ear protection is used. The team may adjust coil position or slowly raise the intensity. These changes can improve comfort without leaving the protocol. A standard course often involves weekday visits for several weeks. Other protocols use much shorter stimulation blocks. Some give more than one session a day or use a different course.

The seven parts of a TMS treatment

Two clinics can use the same platform but deliver different protocols. Two platforms can sometimes deliver similar protocols. A special label may depend on a certain coil or software package. It may also depend on the imaging method or schedule. Ask for all seven layers.

How coils and pulse patterns differ

A figure-eight coil focuses the field near the point where its two loops cross. It is often used for a lateral prefrontal target. An H-coil uses many windings to create a broader field. It is often marketed as Deep TMS. A double-cone coil also gives a broader field that can fit medial targets. A single-pulse migraine device delivers isolated pulses. It is not a multiweek psychiatric rTMS course.

Coils involve a depth-focality tradeoff. This means a tradeoff between depth and focus. Models of many designs found a common pattern. Reaching a wider or somewhat deeper area of cortex tends to reduce focality.[2] Anatomy and coil angle matter. So do intensity, pulse width, and scalp-to-cortex distance. “Deeper” does not mean that a coil directly stimulates every deep region named in a brain-network theory. It also does not prove that one coil works better.

Ten-hertz rTMS delivers ten pulses per second within repeated trains. One-hertz treatment gives one pulse per second. It is often applied to a different side of the prefrontal cortex. Intermittent theta burst stimulation, or iTBS, packs pulses into short bursts. It can reduce stimulation time. Continuous theta burst, or cTBS, uses a different burst pattern. Its use still depends on the condition and protocol.

High frequency is often called excitatory. Low frequency is often called inhibitory. This shorthand comes largely from motor-cortex research. It is not a universal brain on/off switch. Target, dose, and baseline state can change the effect. So can medicines, anatomy, and individual biology.[3]

“Accelerated” means that more than one treatment is given in a day. It can also mean that the course is compressed. It does not name one protocol. SAINT, SWIFT, and other accelerated packages differ in target, dose, and spacing. Their course and evidence also differ. A ten-minute stimulation block can still require a long clinic day. Sessions may need to be spaced apart.

What is FDA-authorized, off label, or investigational?

Many later TMS systems and changes entered through the 510(k) pathway. FDA found them substantially equivalent to a legally marketed predicate for the stated use. The original NeuroStar MDD system received De Novo classification and marketing authorization as a new device type.[9] The original BrainsWay OCD system did too.[10] These terms are not the same as approval of a drug.

The anxiety wording needs special care. Certain systems are cleared to reduce anxiety symptoms in adults who have MDD with comorbid anxiety symptoms.[4] This does not establish treatment for generalized anxiety disorder.

A brief note on smoking cessation

The BrainsWay H4 system has a device-specific 510(k) clearance. It is cleared as an aid in short-term smoking cessation for adults. Its course uses a specified coil, target, dose, schedule, and cue step.[5] “Aid” and “short-term” are essential limits. One pivotal trial was positive.[14] An independent 2024 trial had a null week-12 intention-to-treat result.[15]

Migraine is a separate TMS use

A prescription single-pulse TMS device can deliver isolated pulses near the back of the head. Its label allows acute or preventive migraine use.[6] This handheld approach is different from office-based repetitive TMS in both technical and clinical ways. The office-based form is used for depression, OCD, or PTSD. A psychiatric clinic’s rTMS platform is not automatically cleared to treat migraine. Current U.S. supply and prescription access should be confirmed at the time of care.

Safety and screening

Common effects include scalp discomfort, headache, and tapping. Tingling and brief facial-muscle movement can also occur. These effects often improve as a person adapts. Careful positioning may also help. Ear protection matters because each pulse makes a sharp click.

Seizure is rare, but the risk is not zero. The risk can change with the pulse pattern and dose. It can also change with sleep loss, alcohol or drug withdrawal, neurologic illness, and factors that lower seizure threshold. Those factors include some medicines and health conditions.[3,7] Fainting is also called syncope. It can look alarming, but it is not the same as an epileptic seizure. Staff need a plan to tell them apart and respond.

The team should watch for worsening mood and suicidal thoughts. It should also watch for agitation and possible mania or hypomania. TMS is not a proven stand-alone emergency anti-suicide treatment. Urgent safety concerns require prompt clinical assessment. Studies generally do not show the broad memory problems linked to ECT. Yet “no cognitive effects” is too absolute. Research can miss subtle, short-lived, or individual changes.

Pregnancy and adolescence require added review. So do older age and implants. They are not all automatic reasons to exclude someone. The evidence and label vary by population and device.

Related TMS guides

• TMS for depression: who was studied, how standard and accelerated protocols differ, and what the trials show
• TMS for OCD: the medial target, the symptom-provocation step, and what the pivotal trial found
• TMS for PTSD: what the 2026 MeRT clearance does and does not prove

Response, remission, relapse, and maintenance

Response usually means a meaningful drop on a symptom scale. It often means a drop of about half, but each study may define it differently. Remission means symptoms fall below a set low threshold. It does not promise that symptoms will never return.

A treatment course is the planned acute series. A taper spreads sessions farther apart near the end. Continuation or maintenance treatment aims to hold gains after the acute course. Relapse means symptoms return after improvement or remission. Retreatment means a new course or added sessions after symptoms return.

There is no single maintenance schedule for all people or protocols. Some responders remain well without routine sessions. Others receive a taper, planned maintenance, or retreatment based on symptoms. We know more about acute treatment than the best long-term schedule.

What the research shows

Sham-controlled trials support specific TMS packages for adult depression [16], OCD [13], PTSD [12], and short-term smoking cessation [14]. The amount of repeat evidence differs by use, and the independent smoking replication was null.[15] A large depression trial also compared iTBS with standard 10-Hz treatment. It found iTBS to be noninferior within the tested population and protocol.[8] FDA records show that some later devices did not have a new device-specific pivotal trial. Instead, their records relied on substantial equivalence, literature, real-world data, or bench testing.

Human imaging and physiology studies support one idea. Stimulation at an accessible cortical node can influence a connected network. This is a supported explanation. It does not prove that one network change is the sole cause of improvement.

What we still do not know

We do not have a credible head-to-head ranking of all marketed platforms. We do not know the best target or coil for every person. We also do not know the best dose or maintenance plan for each person. Personalization methods are promising. Yet few trials isolate whether the personalizing step itself improves outcomes. We know less about long-term comparative durability than short-term symptom change. Evidence for many off-label conditions remains small, mixed, or protocol specific.

Questions to ask a TMS clinic

1. What is the exact platform, coil, and FDA number for my proposed use?
2. Is this use on label or off label for my age and diagnosis?
3. What cortical target and localization method will you use?
4. What are the motor-threshold method, intensity, pulses, and full schedule?
5. If treatment is accelerated, how long is the full clinic day, including required breaks?
6. What outcome scale will you use, and how will you define response and remission?
7. How do you screen for implants, seizure risks, mania, worsening mood, and suicidal thoughts?
8. What is the plan if I do not improve, relapse, or need urgent care?

Frequently asked questions

Does the magnet erase memories or control thoughts?

No. TMS delivers timed pulses to a selected area of cortex. It does not read thoughts. Broad memory loss is not an expected treatment goal. Even so, cognitive and mood changes should still be monitored.

Will I be asleep?

Usually not. Standard TMS does not need anesthesia, and patients generally remain awake.

Does TMS hurt?

It can be uncomfortable. People may feel tapping, tingling, pressure, or muscle movement. Careful positioning may improve comfort. A gradual increase in intensity may also help.

How fast does it work?

Timing varies by condition and protocol. Some people notice change during the course. Others notice it later, and some do not respond. A short session does not guarantee a fast clinical response.

Is Deep TMS always stronger or better?

No. An H-coil can create a broader field. Field shape does not prove better clinical outcomes. The diagnosis, target, and full protocol matter. So do the evidence and patient fit.

Can TMS replace medication or therapy?

Sometimes TMS is used with them. Some labels are explicitly adjunctive. Treatment changes should be planned with the prescribing and therapy team. Do not stop medicine suddenly based on general information.

Can any TMS device treat every cleared condition?

No. FDA status is device, coil, protocol, age, and indication specific.

Does insurance cover it?

Coverage and out-of-pocket cost vary by plan, diagnosis, and age. They also vary by device and local policy. The clinic and insurer should confirm current requirements before treatment.

A careful next step

If TMS is being considered, bring the seven-layer checklist and current treatment history to a qualified clinician. Ask for the exact label and evidence behind the proposed protocol. A good visit should make the details clear. It should not hide them behind a brand name.

Medical and crisis disclaimer

This article is for education. It does not diagnose a condition or recommend treatment for an individual. A licensed clinician must review benefits, alternatives, medicines, and implants. The clinician must also review pregnancy status, seizure factors, and urgent safety needs. If you or someone else may act on suicidal thoughts or cannot stay safe, call or text 988 in the United States. You can also call emergency services or go to the nearest emergency department. More crisis resources are listed at the end of this page.

References

1. National Institute of Mental Health. Brain Stimulation Therapies. Updated 2024. NIMH overview.
2. Deng ZD, Lisanby SH, Peterchev AV. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimulation. 2013;6(1):1-13. PMID 22483681. PubMed.
3. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology. 2021;132(1):269-306. PMID 33243615. PubMed.
4. U.S. Food and Drug Administration. BrainsWay Deep TMS System, K210201. 2021. FDA summary.
5. U.S. Food and Drug Administration. BrainsWay Deep TMS System, K200957. 2020. FDA summary.
6. U.S. Food and Drug Administration. SAVI Dual, K230358. 2023. FDA record.
7. McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation in the treatment of depression. Journal of Clinical Psychiatry. 2018;79(1):16cs10905. Full text.
8. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D). Lancet. 2018;391:1683-1692. PMID 29726344. PubMed.
9. U.S. Food and Drug Administration. NeuroStar TMS Therapy System, DEN070003/K061053. Decision October 7, 2008. FDA De Novo database.
10. U.S. Food and Drug Administration. BrainsWay Deep TMS System for OCD, DEN170078. Decision August 17, 2018. FDA De Novo database.
11. U.S. Food and Drug Administration. NeuroStar Advanced Therapy System, adolescent MDD indication, K231926. 2024. FDA summary.
12. U.S. Food and Drug Administration. Wave Neuroscience MeRT System, adjunctive adult PTSD indication, K260402. 2026. FDA summary.
13. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry. 2019;176(11):931-938. PMID 31109199. PubMed.
14. Zangen A, Moshe H, Martinez D, et al. Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double-Blind Randomized Controlled Trial. World Psychiatry. 2021;20(3):397-404. PMID 34505368. PubMed.
15. Bellini BB, et al. Does Deep TMS Really Works for Smoking Cessation? A Prospective, Double Blind, Randomized, Sham Controlled Study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2024;132:110997. PMID 38531486. PubMed.
16. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry. 2007;62(11):1208-1216. PMID 17573044. PubMed.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.